Kavelin Rumalla1, Michelle Lin2, Elliot Orloff2, Li Ding2, Gabriel Zada2, William Mack2, Frank Attenello3. 1. Department of Biomedical and Health Informatics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA. 2. Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. 3. Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA. Electronic address: Frank.Attenello@med.usc.edu.
Abstract
OBJECTIVE: Quality of life is paramount in patients with advanced cancer and may be adversely affected by comorbid depression. We hypothesized that comorbid depression is associated with higher rates of postoperative complications, worse functional outcomes, and higher rates of readmission after craniotomy for resection of malignant intracranial tumors. METHODS: The National Readmissions Database was queried from 2010 to 2014 to identify adult patients undergoing craniotomy for malignant brain tumor resection. The primary psychiatric disease assessed was major depressive disorder (MDD). Outcomes evaluated included neurologic or other major complications, incidence of nonroutine discharge, and unplanned readmission at 30 and 90 days. RESULTS: Of the 57,621 craniotomies for malignant neoplasms included in the analysis, 11.32% of patients had clinically diagnosed MDD. The presence of MDD was associated with nonroutine discharge (odds ratio, 1.10-125; P < 0.0001) as well as higher rates of neurologic complications (odds ratio, 1.03-1.18; P = 0.003). No association between MDD and 30-day or 90-day readmissions was noted. Patients with major All Patient Refined Diagnosis Related Groups severity and index length of stay >7 days experienced higher rates of 30-day and 90-day readmissions. CONCLUSIONS: There is a clinically significant rate of comorbid MDD in patients with malignant intracranial tumors, and MDD is associated with worse perioperative outcomes. Given the wealth of behavioral and pharmaceutical therapies available, MDD is a modifiable risk factor in this cohort that clinicians should be vigilant in screening for and initiating appropriate treatment protocols.
OBJECTIVE: Quality of life is paramount in patients with advanced cancer and may be adversely affected by comorbid depression. We hypothesized that comorbid depression is associated with higher rates of postoperative complications, worse functional outcomes, and higher rates of readmission after craniotomy for resection of malignant intracranial tumors. METHODS: The National Readmissions Database was queried from 2010 to 2014 to identify adult patients undergoing craniotomy for malignant brain tumor resection. The primary psychiatric disease assessed was major depressive disorder (MDD). Outcomes evaluated included neurologic or other major complications, incidence of nonroutine discharge, and unplanned readmission at 30 and 90 days. RESULTS: Of the 57,621 craniotomies for malignant neoplasms included in the analysis, 11.32% of patients had clinically diagnosed MDD. The presence of MDD was associated with nonroutine discharge (odds ratio, 1.10-125; P < 0.0001) as well as higher rates of neurologic complications (odds ratio, 1.03-1.18; P = 0.003). No association between MDD and 30-day or 90-day readmissions was noted. Patients with major All Patient Refined Diagnosis Related Groups severity and index length of stay >7 days experienced higher rates of 30-day and 90-day readmissions. CONCLUSIONS: There is a clinically significant rate of comorbid MDD in patients with malignant intracranial tumors, and MDD is associated with worse perioperative outcomes. Given the wealth of behavioral and pharmaceutical therapies available, MDD is a modifiable risk factor in this cohort that clinicians should be vigilant in screening for and initiating appropriate treatment protocols.
Authors: Adnan I Qureshi; Saqib A Chaudhry; Biggya L Sapkota; Gustavo J Rodriguez; M Fareed K Suri Journal: Arch Phys Med Rehabil Date: 2012-03-21 Impact factor: 3.966
Authors: N Scott Litofsky; Elana Farace; Frederick Anderson; Christina A Meyers; Wei Huang; Edward R Laws Journal: Neurosurgery Date: 2004-02 Impact factor: 4.654
Authors: A M H Krebber; L M Buffart; G Kleijn; I C Riepma; R de Bree; C R Leemans; A Becker; J Brug; A van Straten; P Cuijpers; I M Verdonck-de Leeuw Journal: Psychooncology Date: 2013-09-16 Impact factor: 3.894
Authors: Cesar Ivan Aviles Gonzalez; Matthias Angermeyer; Laura Deiana; Caterina Loi; Elisabetta Murgia; Anita Holzinger; Giulia Cossu; Elena Massa; Ferdinando Romano; Mario Scartozzi; Mauro Giovanni Carta Journal: Clin Pract Epidemiol Ment Health Date: 2021-12-31